We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

The drug will launch within a week, it said, with no news yet on pricing, although Biogen did tell Reuters ... taurursodiol), which launched with a list price of $158,000 per year as an option ...

She added that patients treated with the oral drug in the trial ... launched with a list price of approximately $370,000 per year. It is viewed as a key product for Biogen after a series of ...

People who are 75 and older will compose 10% of the total population in the U.S. by 2030, representing a 7.5% increase from ...

Biogen nonetheless restarted the Federal Drug Administration approval process in 2019 ... In fact, Medicare often pays more than the list price in the short term: For most Part B drugs, it reimburses ...

Widely used prescription medicines could get caught up in the Trump administration's tariff trade wars and EU retaliation.

Research announced today is the first of its kind to suggest that anti-amyloid drugs can delay or even stop the progression ...

Raziel Green / Fox News Soon after her diagnosis, Green learned about a clinical trial at Mass General for an experimental drug — QALSODY® (tofersen), which is made by Biogen in Cambridge ...

To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as Zolgensma, could be approved for a broad range of spinal muscular atrophy ...

Biogen Inc. ( NASDAQ: BIIB) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Great. Good morning, everybody. Happy to be moderating my annual panel where Priya has to listen to me ...